Altimmune To Announce Year End 2020 Financial Results on February 25, 2021
GAITHERSBURG, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its full year 2020 financial results on Thursday, February 25th, 2021.
Altimmune management will host a conference call for investors beginning at 8:30 am ET on Thursday, February 25th, 2021 to discuss financial results and provide a business update.
Conference Call Information:
| Date: | Thursday, February 25, 2021 |
| Time: | 8:30 am Eastern Time |
| Domestic Dial-in: | 877-423-9813 |
| International Dial-in: | 201-689-8573 |
| Conference ID: | 13716171 |
| Webcast: | http://public.viavid.com/index.php?id=143423 |
About Altimmune
Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.
Investor & Media Contacts:
| Will Brown | Stacey Jurchison |
| Chief Financial Officer | Sr. Dir, Investor Relations |
| Phone: 240-654-1450 | Phone : 410-474-8200 |
| wbrown@altimmune.com | sjurchison@altimmune.com |
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
